INCR
Price
$1.48
Change
+$0.11 (+8.03%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
123.5M
24 days until earnings call
KMDA
Price
$6.64
Change
+$0.02 (+0.30%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
306.49M
32 days until earnings call
Ad is loading...

INCR vs KMDA

Header iconINCR vs KMDA Comparison
Open Charts INCR vs KMDABanner chart's image
Intercure
Price$1.48
Change+$0.11 (+8.03%)
VolumeN/A
Capitalization123.5M
Kamada
Price$6.64
Change+$0.02 (+0.30%)
Volume$500
Capitalization306.49M
INCR vs KMDA Comparison Chart
Loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCR vs. KMDA commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Buy and KMDA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (INCR: $1.37 vs. KMDA: $6.62)
Brand notoriety: INCR and KMDA are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: INCR: 413% vs. KMDA: 30%
Market capitalization -- INCR: $123.5M vs. KMDA: $306.49M
INCR [@Pharmaceuticals: Other] is valued at $123.5M. KMDA’s [@Pharmaceuticals: Other] market capitalization is $306.49M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • KMDA’s FA Score: 0 green, 5 red.
According to our system of comparison, INCR is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 4 TA indicator(s) are bullish while KMDA’s TA Score has 5 bullish TA indicator(s).

  • INCR’s TA Score: 4 bullish, 4 bearish.
  • KMDA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than INCR.

Price Growth

INCR (@Pharmaceuticals: Other) experienced а -0.22% price change this week, while KMDA (@Pharmaceuticals: Other) price change was +1.85% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.63%. For the same industry, the average monthly price growth was -1.43%, and the average quarterly price growth was -9.80%.

Reported Earning Dates

INCR is expected to report earnings on Aug 18, 2025.

KMDA is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+4.63% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($306M) has a higher market cap than INCR($124M). KMDA has higher P/E ratio than INCR: KMDA (37.43) vs INCR (22.52). KMDA YTD gains are higher at: 11.817 vs. INCR (-13.698). INCR has higher annual earnings (EBITDA): 25.8M vs. KMDA (22.4M). INCR has more cash in the bank: 103M vs. KMDA (55.6M). KMDA has less debt than INCR: KMDA (8.82M) vs INCR (163M). INCR has higher revenues than KMDA: INCR (415M) vs KMDA (143M).
INCRKMDAINCR / KMDA
Capitalization124M306M41%
EBITDA25.8M22.4M115%
Gain YTD-13.69811.817-116%
P/E Ratio22.5237.4360%
Revenue415M143M290%
Total Cash103M55.6M185%
Total Debt163M8.82M1,848%
FUNDAMENTALS RATINGS
INCR vs KMDA: Fundamental Ratings
INCR
KMDA
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9479
PRICE GROWTH RATING
1..100
6247
P/E GROWTH RATING
1..100
472
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (58) in the Servicestothe Health Industry industry is in the same range as KMDA (75) in the Biotechnology industry. This means that INCR’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.

KMDA's SMR Rating (79) in the Biotechnology industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.

KMDA's Price Growth Rating (47) in the Biotechnology industry is in the same range as INCR (62) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is significantly better than the same rating for KMDA (72) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRKMDA
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 2 days ago
67%
Declines
ODDS (%)
Bearish Trend 16 days ago
80%
Bearish Trend 18 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
63%
View a ticker or compare two or three
Ad is loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABVYX16.03N/A
N/A
AB Large Cap Value Advisor
MLPRX4.69N/A
N/A
Invesco SteelPath MLP Income C
NCAVX11.28N/A
N/A
Nuance Concentrated Value Investor
CFIGX13.22N/A
N/A
Columbia Flexible Capital Income C
JTQAX14.48N/A
N/A
JHancock ESG International Equity A

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and RDY have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and RDY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+0.61%
RDY - KMDA
33%
Poorly correlated
+2.34%
NXSCF - KMDA
27%
Poorly correlated
N/A
SGIOY - KMDA
27%
Poorly correlated
-0.48%
INCR - KMDA
26%
Poorly correlated
-6.01%
ASRT - KMDA
25%
Poorly correlated
+4.20%
More